Breast Cancer Clinical Trial
Magnetic Resonance Imaging in Radiotherapy for Breast Cancer
Summary
This is a single-center, prospective pilot study evaluating feasibility and efficacy of incorporating magnetic resonance imaging (MRI) simulation into the planning of radiation treatment (RT) for breast cancer.
Full Description
PRIMARY OBJECTIVE:
I. To determine feasibility of acquiring MRI simulation prior to RT planning.
EXPLORATORY OBJECTIVE:
I. To determine change in target volume with MRI simulation compared to Computerized tomography (CT) simulation.
OUTLINE: MRI simulation will be performed once at baseline. There is no follow up planned for study purposes. Patients will be followed as part of their regular clinical care.
Eligibility Criteria
Inclusion Criteria:
Participants with an Eastern Cooperative Oncology Group (ECOG) performance status <=2 (or Karnofsky ≥>=60%, see Appendix A).
Participants with the ability to understand and the willingness to sign a written informed consent document.
Participants may separately enroll on therapeutic clinical trials when they enroll on this trial. Note: All interventions on this protocol are standard of care, so enrollment on other therapeutic protocols is allowed at the discretion of the treating physician.
Patients must have pathologically confirmed invasive or in situ breast cancer.
Patients must have tumors in which adjuvant breast radiotherapy following breast conserving surgery is indicated, as determined by the treating physician.
Patients must be female. Note: Male patients are excluded due to the rarity of male breast cancer and difficulty in pursuing breast conserving surgery for male patients.
Exclusion Criteria:
Participants with a contraindication to MRI per the MRI checklist.
Patients with breast tumor or tumor bed not visualized at CT or MRI during RT planning.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
San Francisco California, 94143, United States More Info
Principal Investigator
How clear is this clinincal trial information?